Syndax Pharmaceuticals Stock Drops After Axatilimab Trial Failure
What happened
Syndax Pharmaceuticals announced that its Phase 2 MAXPIRe trial for axatilimab failed to meet its primary endpoint in idiopathic pulmonary fibrosis (IPF) on October 13, 2026. The trial, which measured the annualized rate of decline in forced vital capacity (FVC), showed no benefit for axatilimab on that endpoint. Following the announcement, Syndax Pharmaceuticals shares fell 11.72% from the October 12 close. The company stated it would not pursue further study of axatilimab in IPF, though its graft-versus-host disease programs continue. SueWallSt has notified investors of a pending investigation into potential securities law violations for those who lost money.
From prnewswire.com
Why it matters
The failure of the axatilimab trial impacts Syndax Pharmaceuticals' pipeline, forcing the company to halt further research into the drug for IPF. This news follows prior statements from Chief Medical Officer Botwood who had described the study as having the potential to provide robust proof-of-concept data for axatilimab in IPF. The failure could also impact the value of the exclusive co-development partnership between Syndax Pharmaceuticals and Incyte.
Shares of Syndax Pharmaceuticals were traded on the Nasdaq stock exchange on August 12, 2026.
From prnewswire.com
Who's involved
- Syndax PharmaceuticalsCompany whose shares dropped after the clinical trial failure
- IncyteAmerican pharmaceutical company with an exclusive co-development partnership with Syndax Pharmaceuticals
- FDARegulatory body that grants approvals and priority reviews for Syndax Pharmaceuticals' therapeutic pipeline
- NasdaqStock exchange where Syndax Pharmaceuticals shares are traded
- BotwoodChief Medical Officer for Syndax Pharmaceuticals